1. Recker RR, Hinders S, Davies KM, Heaney RP, Stegman MR, Kimmel DB, et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996;11:1961-1966.
2. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial [see comments]. Am J Med 1995;98:331-335.
3. Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis [see comments]. Am J Clin Nutr 1998;67:18-24.
4. Kimble RB, Bain S, Pacifici R. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 1997;12:935-941.
5. Gallagher JC, Riggs BL, DeLuca HF. Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J Clin Endocrinol Metab 1980;51:1359-1364.
6. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;274(21):199-208. [see comments] [published erratum appears in JAMA 1995 Dec 6; 274(21): 1676].
7. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, Watts NB, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-1738.
8. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Wassertheil-Smoller S, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
9. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Mysiw WJ. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-2684.
10. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Baylink D, et al. PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000;109:267-276.
11. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Yanover MJ, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis [see comments]. N Engl J Med 1990;323:73-79.
12. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Favus M, et al. The Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group [see comments]. N Engl J Med 1995;333:1437-1443. [see comments].
13. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Ensrud KE, et al. Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541. [see comments].
14. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Miller PD, et al. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-1352.
15. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Cummings SR, et al. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-645. [see comments].
16. Canalis E, Centrella M, Burch W, McCarthy TL. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 1989;83:60-65.
17. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Mitlak BH, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
18. Marie PJ. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate. Osteoporos Int 2003;14:Suppl 3. S9-S12.
19. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Reginster JY, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-468.